Skip to Main Content

Latest News

  • Nikayin, Ostroff: Advanced Training in Interventional Psychiatry

    Sina Nikayin, MD, assistant professor of psychiatry, and Robert Ostroff, MD, co-medical director of the Interventional Psychiatry Service at Yale New Haven Psychiatric Hospital, are co-authors of a paper in Journal of the Neurological Sciences that describes interventional psychiatry training at Yale New Haven Psychiatric Hospital.

    Source: Journal of the Neurological Sciences
    Read more
  • The Ketamine Cure

    How safe is the anesthetic ketamine in the treatment of chronic depression? Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry and Director of the Yale Depression Research Program, offered perspective in a recent New York Times article.

    Source: The New York Times
    Read more
  • Researchers Are Closer to Explaining How Ketamine Treats Depression

    Ketamine, the anesthetic and pain-relieving drug sometimes used for hallucinogenic effects, could revolutionize mental health care. Yet, how and why the drug relieves depression symptoms is still clouded in mystery."Like many advances in psychiatry, the clinical breakthrough occurred before we understood how it worked to alleviate depression," John H. Krystal, MD, Chair of the Yale Department of Psychiatry, told Verywell via email.

    Source: Verywell Health
    Read more
  • Wilkinson: What is the Deal with Esketamine?

    Samuel Wilkinson, MD, Assistant Professor of Psychiatry and Assistant Director of the Yale Depression Research Program, writes in Psychiatric Times about the drug esketamine, approved by the U.S. Food and Drug Administration last year as the first rapid-acting therapy for treatment-resistant depression.

    Source: Psychiatric Times
    Read more